Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Chronic Lymphocytic Leukemia — An Interview with Dr Lindsey Roeker on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting

48:23
 
Share
 

Manage episode 484771578 series 2530615
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Featuring an interview with Dr Lindsey Roeker, including the following topics:

  • Clinical development of novel Bruton tyrosine kinase (BTK) degraders in therapy for chronic lymphocytic leukemia (CLL) (0:00)
  • Safety of BTK inhibitors in older and frail patients with CLL (3:41)
  • Utility of minimal residual disease-guided treatment with venetoclax/obinutuzumab (9:20)
  • Impact of the AMPLIFY study of acalabrutinib with venetoclax with or without obinutuzumab in CLL (16:32)
  • Utility of acalabrutinib, venetoclax and obinutuzumab for high-risk CLL (23:31)
  • Emerging data with sonrotoclax and zanubrutinib in treatment-naïve CLL (25:16)
  • Sequencing, tolerability and future development involving pirtobrutinib (25:57)
  • Emerging data with the addition of a BTK inhibitor to chimeric antigen receptor T-cell therapy (32:28)
  • Clinical considerations in the management of Richter’s transformation (38:14)
  • Survival outcomes and quality of life for patients with CLL (41:02)
  • Ongoing and future efforts to improve CLL treatment outcomes (45:01)

CME information and select publications

  continue reading

1494 episodes

Artwork
iconShare
 
Manage episode 484771578 series 2530615
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Featuring an interview with Dr Lindsey Roeker, including the following topics:

  • Clinical development of novel Bruton tyrosine kinase (BTK) degraders in therapy for chronic lymphocytic leukemia (CLL) (0:00)
  • Safety of BTK inhibitors in older and frail patients with CLL (3:41)
  • Utility of minimal residual disease-guided treatment with venetoclax/obinutuzumab (9:20)
  • Impact of the AMPLIFY study of acalabrutinib with venetoclax with or without obinutuzumab in CLL (16:32)
  • Utility of acalabrutinib, venetoclax and obinutuzumab for high-risk CLL (23:31)
  • Emerging data with sonrotoclax and zanubrutinib in treatment-naïve CLL (25:16)
  • Sequencing, tolerability and future development involving pirtobrutinib (25:57)
  • Emerging data with the addition of a BTK inhibitor to chimeric antigen receptor T-cell therapy (32:28)
  • Clinical considerations in the management of Richter’s transformation (38:14)
  • Survival outcomes and quality of life for patients with CLL (41:02)
  • Ongoing and future efforts to improve CLL treatment outcomes (45:01)

CME information and select publications

  continue reading

1494 episodes

Todos os episódios

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Listen to this show while you explore
Play